Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PTGER1 | P34995 | 5/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.41 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.39 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.36 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.36 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL963406 | 0.91 | MEN1 (0.45) | MEN1KMT2APTGER1AKR1B1NLRP3 | |
| SCHEMBL958290 | 0.80 | CNR1 (0.37) | MEN1KMT2APTGER1AKR1B1SLC6A4 | |
| SCHEMBL961733 | 0.79 | MEN1 (0.50) | MEN1KMT2APTGER1NLRP3 | |
| SCHEMBL958431 | 0.76 | NLRP3 (0.35) | MEN1KMT2APTGER1AKR1B1NLRP3 | |
| SCHEMBL958430 | 0.71 | NLRP3 (0.35) | MEN1KMT2APTGER1NLRP3 | |
| SCHEMBL8603506 | 0.68 | LMNA (0.52) | KMT2AKCNH2 | |
| SCHEMBL14627346 | 0.68 | CYP1A2 (0.53) | PTGER1AKR1B1 | |
| SCHEMBL14627391 | 0.67 | CYP1A2 (0.53) | PTGER1AKR1B1 | |
| SCHEMBL1551626 | 0.67 | CYP1A2 (0.49) | MEN1KMT2APTGER1 | |
| SCHEMBL1552066 | 0.67 | MEN1 (0.43) | MEN1KMT2APTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071628-B2 | Indazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-20110015234-A1 | INDAZOLE DERIVATIVES | ACKERMANN JEAN | 2011-01-20 | — | — | US | disclosed |
| US-7858645-B2 | Indazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-12-28 | — | — | US | disclosed |
| EP-2079703-A1 | INDAZOLE DERIVATIVES USEFUL AS L-CPT1 INHIBITORS | F. Hoffmann-Roche AG (CH) | 2009-07-22 | — | — | EP | disclosed |
| EP-1828199-B1 | THIENO-PYRIDINE DERIVATIVES AS GABA-B ALLOSTERIC ENHANCERS | HOFFMANN LA ROCHE (CH) | 2009-05-06 | — | — | EP | disclosed |
| US-7390903-B2 | Thieno-pyridine derivatives as allosteric enhancers of the GABAB receptors | HOFFMANN-LA ROCHE INC. (US) | 2008-06-24 | — | — | US | disclosed |
| WO-2008052898-A1 | INDAZOLE DERIVATIVES USEFUL AS L-CPT1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-05-08 | — | — | WO | disclosed |
| US-20080103182-A1 | INDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2008-05-01 | — | — | US | disclosed |
| EP-1828199-A1 | THIENO-PYRIDINE DERIVATIVES AS GABA-B ALLOSTERIC ENHANCERS | F. Hoffmann-Roche AG (CH) | 2007-09-05 | — | — | EP | disclosed |
| US-20060135552-A1 | Thieno-pyridine derivatives as allosteric enhancers of the GABAB receptors | HOFFMANN-LA ROCHE INC. | 2006-06-22 | — | — | US | disclosed |
| WO-2006063732-A1 | THIENO-PYRIDINE DERIVATIVES AS GABA-B ALLOSTERIC ENHANCERS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-06-22 | — | — | WO | disclosed |
| US-4600428-A | N-(cyclopropyl-pyrimidinyl-N'-(aryl-sulfonyl) ureas having herbicidal activity | CIBA-GEIGY CORPORATION (US) | 1986-07-15 | — | — | US | disclosed |
| US-4515626-A | PLANT GROWTH REGULATORS | CIBA GEIGY CORPORATION (US) | 1985-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135552-A1 | Thieno-pyridine derivatives as allosteric enhancers of the GABAB receptors | GABBR1, CHRNA5, CHRNA3 | MEN1 4709/4885KMT2A 3171/4885PTGER1 388/4885 |
| US-20080103182-A1 | INDAZOLE DERIVATIVES | CPT1A, CPT1B, CES1 | MEN1 3398/4885KMT2A 3304/4885PTGER1 396/4885 |
| US-20110015234-A1 | INDAZOLE DERIVATIVES | CPT1A, CPT1B, CES1 | MEN1 3398/4885KMT2A 3304/4885PTGER1 396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.